Probiotic composition for relieving sarcopenia obesity and application thereof

Abstract

The invention relates to the technical field of biology, and provides a probiotic composition for relieving sarcopenia obesity and application of the probiotic composition. The composition comprises at least two of lactobacillus plantarum, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Wherein the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.25839; the preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) No.26968; the preservation number of the animal bifidobacterium subsp. Lactis is CGMCC (China General Microbiological Culture Collection Center) No. 27998. The composition disclosed by the invention can be used for increasing the muscle content of an organism, improving the muscle tissue form, increasing adenosine triphosphate and inhibiting abnormal increase of body weight, so that the composition can be used for effectively preventing and treating sarcopenia obesity.

Description

Technical Field

[0001] The present invention relates to the field of biotechnology. Specifically, the present invention relates to a probiotic composition for alleviating sarcopenic obesity and its application. Background Art

[0002] Sarcopenic obesity (SO) is a chronic disease in which obesity and sarcopenia (hereinafter referred to as sarcopenia) coexist. Sarcopenia is a skeletal muscle motor system disease, and its main characteristics are the decline of muscle mass, muscle strength, and muscle function. The pathogenesis of sarcopenic obesity is complex, including aging, improper lifestyle (sedentary, improper diet, lack of exercise), inflammation, and complications of acute and chronic diseases. This dual pressure of muscle loss and fat accumulation can cause complications such as weakness, disability, falls, fractures, metabolic diseases, and cancer, so the related mortality rate is increasing. With the further deepening of the aging of the population and the increasing number of obese people, the incidence of sarcopenic obesity is increasing, and it has become an important global public health problem.

[0003] At present, the treatment methods for sarcopenic obesity mainly include dietary intervention, exercise therapy, and drug therapy. Dietary intervention requires patients to strictly control their diet structure and calorie intake, and it is difficult to adhere to in the long term; exercise therapy has certain requirements for the patient's physical condition and exercise ability, and it is difficult to implement for some elderly patients or physically weak patients; existing drug therapies have problems such as large side effects and uncertain efficacy.

[0004] Therefore, it is of great practical significance to develop a safe, effective, and easy-to-use product for alleviating sarcopenic obesity. Summary of the Invention

[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to some extent. The present invention provides a composition capable of effectively alleviating sarcopenic obesity, which composition comprises at least two of the following three probiotics: Lactobacillus plantarum, Lactobacillus rhamnosus, and Bifidobacterium animalis subsp. lactis. The inventors have conducted in-depth research and found that the composition of the present invention has multiple effects in improving sarcopenic obesity. It can enhance the muscle content of the body, improve the morphological structure of muscle tissue, and thereby enhance the functionality of muscles. At the same time, the composition can also effectively increase the content of adenosine triphosphate (ATP) in the body, provide more abundant energy, and thus improve exercise ability. In addition, it can effectively inhibit the abnormal increase in body weight, thereby achieving a comprehensive improvement of sarcopenic obesity.

[0006] In a first aspect of the present invention, there is provided a composition comprising probiotics. According to an embodiment of the present invention, the composition comprises: Lactobacillus plantarum ( Lactobacillus plantarum ), Lactobacillus rhamnosus ( Lactobacillus rhamnosus ), and at least two of Lactobacillus plantarum subsp. lactis ( Bifidobacterium animalis subsp. lactis ); wherein, the preservation unit of the Lactobacillus plantarum is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms, the preservation time is September 28, 2022, and the preservation number is CGMCC No. 25839; the preservation unit of the Lactobacillus rhamnosus is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms, the preservation time is March 31, 2023, and the preservation number is CGMCC No. 26968; the preservation unit of the Bifidobacterium animalis subsp. lactis is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms, the preservation time is July 24, 2023, and the preservation number is CGMCC No. 27998.

[0007] According to an embodiment of the present invention, the composition containing probiotics may further include at least one of the following additional technical features: According to an embodiment of the present invention, the Lactobacillus plantarum, the Lactobacillus rhamnosus, and the Bifidobacterium animalis subsp. lactis are independently viable bacteria, inactivated bacteria, or a combination thereof.

[0008] According to an embodiment of the present invention, the total effective viable bacteria count of the Lactobacillus plantarum, the Lactobacillus rhamnosus, and the Bifidobacterium animalis subsp. lactis is not less than 1×10 6 CFU / g.

[0009] According to an embodiment of the present invention, the ratio of the viable bacteria count of the Lactobacillus plantarum, the Lactobacillus rhamnosus, and the Bifidobacterium animalis subsp. lactis is (1-5):(1-5):(1-5).

[0010] In the second aspect of the present invention, the present invention provides a product containing a probiotic composition. According to an embodiment of the present invention, the product includes the composition described in the first aspect.

[0011] According to an embodiment of the present invention, the product containing a probiotic composition may further include at least one of the following additional technical features: According to an embodiment of the present invention, the product includes any one of drugs, foods, and health products.

[0012] According to an embodiment of the present invention, the drug further includes a pharmaceutically acceptable carrier.

[0013] According to an embodiment of the present invention, the food further includes edible raw and auxiliary materials.

[0014] In the third aspect of the present invention, the present invention provides the use of the composition described in the first aspect or the product described in the second aspect in the preparation of a drug for preventing and treating sarcopenic obesity.

[0015] In the fourth aspect of the present invention, there is provided an application of the composition described in the first aspect or the product described in the second aspect, and the application is selected from at least one of the following: Application in the preparation of a preparation for increasing muscle mass; Application in the preparation of a preparation for improving exercise ability; Application in the preparation of a preparation for increasing ATP content; Application in the preparation of a preparation for improving the morphology of muscle tissue; Application in the preparation of a preparation for reducing body weight.

[0016] Through a large number of experiments, the inventors found that when three probiotics, Lactobacillus plantarum, Lactobacillus rhamnosus, and Bifidobacterium animalis subsp. lactis, are used in combination, sarcopenic obesity can be effectively alleviated. Therefore, the composition or product containing the above three probiotics can increase the muscle mass of the body, improve the morphology of muscle tissue, increase adenosine triphosphate, and at the same time effectively inhibit the abnormal increase in body weight, thereby effectively preventing and treating sarcopenic obesity.

[0017] The additional aspects and advantages of the present invention will be partly given in the following description, partly become apparent from the following description, or be understood through the practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The above and / or additional aspects and advantages of the present invention will become apparent and be readily understood from the description of the embodiments in conjunction with the following drawings, wherein: 图1 is a graph showing the experimental results of the efficacy of probiotic powder in improving sarcopenia (total movement distance) according to Example 1 of the present invention. Compared with the model control group, * P <0.05, ** P <0.01, *** P <0.001; 图2 is a graph showing the experimental results of the efficacy of probiotic powder in improving sarcopenia (ATP content) according to Example 2 of the present invention. Compared with the model control group, * P <0.05, ** P <0.01, *** P <0.001; 图3 is a typical pathological section of zebrafish muscle tissue after sample treatment according to Example 3 of the present invention; 图4 is a graph showing the effect of the composite probiotic on the weight gain of mice according to Example 4 of the present invention. Compared with the model control group, ** P <0.01. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0019] Embodiments of the present invention will be described in detail below. The embodiments described below are exemplary and are only used to explain the present invention and should not be construed as a limitation of the present invention.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the technical field to which this invention belongs. The terms used in the specification of the present invention herein are only for the purpose of describing embodiments and examples, and are not intended to limit the present invention.

[0021] Unless otherwise stated or there is a contradiction, the terms or phrases used herein have the following meanings: In the present invention, the terms "a plurality of", "multiple types", "multiple times", etc., unless otherwise specified, mean greater than or equal to 2 in number. For example, "one or more types" means one type or greater than or equal to two types.

[0022] The "combinations thereof", "any combinations thereof", "any combination manners thereof", etc. used herein include all suitable combination manners of any two or more than two items in the listed items.

[0023] In this article, the terms "containing", "including" or "comprising" are open expressions, that is, including the content specified in the present invention, but not excluding other aspects of the content.

[0024] In the present invention, regarding numerical intervals (that is, numerical ranges), unless otherwise specified, the distribution of the selectable numerical values within the numerical interval is regarded as continuous, and includes the two numerical endpoints of the numerical interval (that is, the minimum value and the maximum value), as well as each numerical value between these two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to the integers within the numerical interval, it includes the two endpoint integers of the numerical range, as well as each integer between the two endpoints, which is equivalent to directly listing each integer. When providing multiple numerical ranges to describe features or characteristics, these numerical ranges can be combined. In other words, unless otherwise specified, the numerical ranges disclosed herein should be understood to include any and all sub-ranges subsumed therein. The "numerical values" in the numerical interval can be any quantitative values, such as numbers, percentages, ratios, etc. The "numerical interval" allows a broad inclusion of quantitative intervals such as percentage intervals, ratio intervals, ratio value intervals, etc.

[0025] In the present invention, regarding the units of data ranges, if there is only a unit after the right endpoint, it means that the units of the left endpoint and the right endpoint are the same. For example, 3 - 5h means that the units of the left endpoint "3" and the right endpoint "5" are both h (hours).

[0026] As used herein, the alternative scopes of the terms "and / or", "or / and", and "and / or" include any one of two or more related listed items, and also include any and all combinations of the related listed items. The any and all combinations include combinations of any two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, this technical solution undoubtedly includes the technical solution connected by "logical AND", and also undoubtedly includes the technical solution connected by "logical OR". For example, "A and / or B" includes three parallel solutions: A, B, and A + B. Another example is the technical solution of "A, and / or, B, and / or, C, and / or, D", which includes any one of A, B, C, and D (that is, the technical solution connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, includes combinations of any two or any three of A, B, C, and D, and also includes the four-item combination of A, B, C, and D (that is, the technical solution connected by "logical AND").

[0027] Affected by disorders of fat metabolism, acute / chronic complications, and aging-related metabolic changes, the loss of skeletal muscle mass and function is common in obese individuals. Overweight with low muscle mass or function is called sarcopenic obesity (SO). Such conditions predict poor clinical outcomes, and there is an urgent need to propose effective prevention and treatment strategies for SO.

[0028] As a type of active microorganisms beneficial to the host, probiotics have received extensive attention in improving human metabolic health in recent years. Studies have found that the imbalance of the gut microbiota is closely related to the occurrence and development of sarcopenic obesity, and regulating the gut microbiota may become a new way to alleviate sarcopenic obesity. However, there is currently no highly effective probiotic composition specifically for sarcopenic obesity on the market.

[0029] In view of this, the inventors have studied a variety of probiotics and found that when Lactobacillus plantarum, Lactobacillus rhamnosus, and Bifidobacterium animalis subsp. lactis are used in combination, they can have multiple effects in improving sarcopenic obesity. It can enhance the muscle content of the body, improve the morphology of muscle tissue, and then enhance the functionality of muscles. At the same time, it can effectively increase the content of adenosine triphosphate (ATP) in the body, provide more abundant energy, and thus improve exercise ability. In addition, it can effectively inhibit the abnormal increase in body weight, thereby achieving a comprehensive improvement of sarcopenic obesity. The composition, product, and its application containing the three bacteria will be introduced in detail below.

[0030] Composition containing probiotics In the first aspect of the present invention, the present invention provides a composition comprising probiotics. According to an embodiment of the present invention, the composition comprising probiotics includes at least two of Lactobacillus plantarum ( Lactobacillus plantarum ), Lactobacillus rhamnosus ( Lactobacillus rhamnosus ), and Bifidobacterium animalis subsp. lactis ( Bifidobacterium animalis subsp. lactis ); wherein, the preservation unit of the Lactobacillus plantarum is the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, the preservation time is September 28, 2022, and the preservation number is CGMCC No. 25839; the preservation unit of the Lactobacillus rhamnosus is the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, the preservation time is March 31, 2023, and the preservation number is CGMCC No. 26968; the preservation unit of the Bifidobacterium animalis subsp. lactis is the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, the preservation time is July 24, 2023, and the preservation number is CGMCC No. 27998.

[0031] Through a large number of experiments, the inventors found that when Lactobacillus plantarum, Lactobacillus rhamnosus, and Bifidobacterium animalis subsp. lactis are used in combination, they can effectively alleviate sarcopenic obesity. Therefore, the composition containing these three probiotics can have multiple effects in improving sarcopenic obesity. It can enhance the muscle content of the body, improve the muscle tissue morphology, and then enhance the functionality of the muscles. At the same time, the composition can also effectively increase the content of adenosine triphosphate (ATP) in the body, provide more abundant energy, and thus improve the exercise ability. In addition, it can effectively inhibit the abnormal increase in body weight, thereby achieving a comprehensive improvement of sarcopenic obesity.

[0032] It should be noted that the "Lactobacillus plantarum", "Lactobacillus rhamnosus", and "Bifidobacterium animalis subsp. lactis" described in the present invention are all known and publicly disclosed strains. Specifically, the relevant information of the "Lactobacillus plantarum" described in the present invention has been clearly disclosed in Patent CN119372076A, the relevant information of the "Lactobacillus rhamnosus" described in the present invention has been clearly disclosed in Patent CN117126788A, and the relevant information of the "Bifidobacterium animalis subsp. lactis" described in the present invention has been clearly disclosed in Patent CN117448198A.

[0033] In some embodiments of the present invention, the Lactobacillus plantarum can be live bacteria, or Lactobacillus plantarum that has been inactivated, genetically recombined, modified, attenuated, chemically treated, physically treated and retains all or part of its original biological activity, or it can be the lysate, culture (such as supernatant) of the bacteria, or the components extracted from the culture supernatant.

[0034] In some embodiments of the present invention, the Lactobacillus rhamnosus may be viable bacteria, or may be Lactobacillus rhamnosus that has been inactivated, genetically recombined, modified or altered, attenuated, chemically treated, physically treated, and retains all or part of its original biological activity. It may also be a lysate of the bacterial cells, a culture (such as a supernatant), or a component extracted from the above culture.

[0035] In some embodiments of the present invention, the Bifidobacterium animalis subsp. lactis may be viable bacteria, or may be Bifidobacterium animalis subsp. lactis that has been inactivated, genetically recombined, modified or altered, attenuated, chemically treated, physically treated, and retains all or part of its original biological activity. It may also be a lysate of the bacterial cells, a culture (such as a supernatant), or a component extracted from the above culture.

[0036] In some embodiments of the present invention, the total effective viable count of the Lactobacillus plantarum, the Lactobacillus rhamnosus, and the Bifidobacterium animalis subsp. lactis is not less than 1×10 6 CFU / g. For example, it may be 1×10 6 CFU / g, 1×10 7 CFU / g, 1×10 8 CFU / g, 1×10 9 CFU / g, 1×10 10 CFU / g, 1×10 11 CFU / g, 1×10 12 CFU / g, etc., or may be a range composed of any of the above values. Thus, the composition can effectively increase the muscle content of the body, improve the muscle tissue morphology, increase the content of adenosine triphosphate (ATP), and inhibit the abnormal increase in body weight, thereby effectively preventing and treating sarcopenic obesity.

[0037] In some embodiments of the present invention, the ratio of the viable counts of the Lactobacillus plantarum, the Lactobacillus rhamnosus, and the Bifidobacterium animalis subsp. lactis is (1~5):(1~5):(1~5). For example, it may be 1:1:1, 1:1:2, 1:3:1, 4:1:2, 5:1:5, etc., or may be a range composed of any of the above values. Thus, by making the ratio of the viable counts of the three probiotics within the above range, the composition can effectively increase the muscle content of the body, improve the muscle tissue morphology, the content of adenosine triphosphate (ATP), and inhibit the abnormal increase in body weight, thereby effectively preventing and treating sarcopenic obesity.

[0038] Products containing the probiotic composition In a second aspect of the present invention, the present invention provides a product comprising a probiotic composition. According to an embodiment of the present invention, the product comprises the composition described in the first aspect. As mentioned above, the composition of the present invention can effectively increase the muscle mass of the body, improve the morphology of muscle tissue, increase the content of adenosine triphosphate (ATP), and inhibit the abnormal increase in body weight, thereby effectively preventing and treating sarcopenic obesity. Therefore, the product of the present invention can effectively prevent and treat sarcopenic obesity.

[0039] In some embodiments of the present invention, the product comprises any one of a drug, a food, and a health product.

[0040] In some embodiments of the present invention, the drug is a pharmaceutical product.

[0041] In the present invention, a "drug" includes any medicament, compound, composition, or mixture that provides a pharmacological effect in vivo or in vitro, and usually provides a beneficial effect. The range of the pharmacological effect produced by the "drug" in vivo is not particularly limited, and it can be a systemic effect or only a local effect. The activity of the "drug" is not particularly limited, and it can be an active substance that can interact with other substances or an inert substance that does not interact.

[0042] In the present invention, a "pharmaceutical product" is a pharmaceutical preparation that can be directly administered, and it usually has a specified usage and dosage.

[0043] In some embodiments of the present invention, the drug further comprises a pharmaceutically acceptable carrier.

[0044] In the present invention, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of reasonable medical judgment and are commensurate with a reasonable benefit / risk ratio.

[0045] In the present invention, "pharmaceutically acceptable carrier" refers to pharmaceutically acceptable materials, compositions or media, such as liquid or solid fillers, diluents, excipients, solvents or encapsulating materials. As used herein, the phrase "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delaying agents and the like that are compatible with the administration of the drug. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch, potato starch and substituted or unsubstituted β-cyclodextrin; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) diols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer; and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0046] In some embodiments of the present invention, the dosage form of the drug is tablets, capsules, granules, pills, ointments, solutions, suspensions, emulsions, creams, sprays, drops, patches or tube feeding preparations.

[0047] In some embodiments of the present invention, the drug may further include other pharmaceutically active ingredients. The other pharmaceutically active ingredients may be drug ingredients having an effect on preventing and treating sarcopenia or obesity, or may be drug ingredients having an effect on preventing and treating other diseases.

[0048] In the present invention, "health care product" has the same meaning as "health food" and can be used interchangeably. In the present invention, "health care product" refers to a food with health care functions, which can regulate the physiological functions of animals (humans or other animals), and usually provides beneficial effects. There is no particular limitation on the range of beneficial effects produced by "health care products" in the body, which can be systemic effects or only local effects.

[0049] In some embodiments of the present invention, the dosage form of the health care product is pills, tablets, granules, capsules, solutions, suspensions or emulsions. Further, non-limiting examples include honeyed pills, hydrated honeyed pills, water pills, syrups, syrup preparations, etc.

[0050] In the present invention, "food" refers to products that can be directly consumed. It should be understood that the food in the present invention may contain, in addition to the aforementioned Lactobacillus plantarum, Lactobacillus rhamnosus, and Bifidobacterium animalis subsp. lactis, any other suitable edible substances. In some embodiments, the other edible substances may be selected from substances permitted to be added in food management regulations, and further, do not include substances prohibited from being added in food management regulations. Unless otherwise specified, the food management regulations refer to the current regulations during production.

[0051] In some embodiments of the present invention, the food further includes edible raw and auxiliary materials.

[0052] In the present invention, "edible raw and auxiliary materials" refers to edible raw materials, edible auxiliary materials, or a combination of both. Among them, "edible raw materials" refers to edible substances that can provide health care functions alone; "edible auxiliary materials" refers to edible substances that do not have the function of providing health care alone. It should be understood that "edible raw and auxiliary materials" can be selected from substances permitted to be added in health product management regulations, and further, do not include substances prohibited from being added in health product management regulations. Unless otherwise specified, the health product management regulations refer to the current regulations during production.

[0053] In some embodiments of the present invention, examples of edible auxiliary materials include edible sugar, fructose, honey, glucose, starch, vitamins, beneficial trace elements and medium elements (such as calcium powder), soybean powder, mung bean powder, maltodextrin, milk powder, vegetable juice, fruit juice, spices, flavors, etc. The edible auxiliary materials of the present invention can be used singly or in combination.

[0054] Applications and Methods In the third aspect of the present invention, the present invention provides the use of the composition described in the first aspect or the product described in the second aspect in the preparation of a drug for preventing and treating sarcopenic obesity.

[0055] In the present invention, "prevent and treat" has the same meaning as "prevent and / or treat" and can be used interchangeably. In the present invention, "prevent and treat" includes aspects such as prevention, treatment, and adjuvant treatment. As used herein, "prevent and treat" means to relieve, delay the progression, attenuate, prevent, or maintain an existing disease or disorder. "Prevent and treat" also includes curing one or more symptoms of a disease or disorder, preventing its development, or alleviating it to a certain extent.

[0056] In the fourth aspect of the present invention, the present invention provides the use of the composition described in the first aspect or the product described in the second aspect, and the use is selected from at least one of the following: use in the preparation of a preparation for increasing muscle mass; use in the preparation of a preparation for improving exercise ability; use in the preparation of a preparation for increasing ATP content; use in the preparation of a preparation for improving the morphology of muscle tissue; use in the preparation of a preparation for reducing body weight.

[0057] In some embodiments of the present invention, in the above applications, the preparation includes a pharmaceutical preparation or a food preparation. It should be noted that the composition or product can be prepared into food and medicine.

[0058] In some embodiments, the pharmaceutical preparation can be a liquid preparation or a solid preparation. A liquid preparation refers to a preparation containing a liquid phase, and non-limiting examples include solutions, suspensions, emulsions, etc. Non-limiting examples of solid preparations include tablets, capsules, granules, pills, etc. In some embodiments, according to different administration methods, the pharmaceutical preparation can be an oral preparation, an injection, a drop, a patch, a tube feeding preparation, etc.

[0059] In the fifth aspect of the present invention, the present invention provides a method for preventing and treating sarcopenic obesity, which is characterized by comprising: administering to a subject a therapeutically effective amount of the composition described in the first aspect or the product described in the second aspect.

[0060] In the present invention, the "subject" is an animal, preferably a mammal, more preferably a human. The subjects include, but are not limited to, consumers of health products and patients with diseases, disorders and / or symptoms. The subjects in the present invention are preferably mammals. The term "mammal" mainly refers to warm-blooded vertebrate mammals, including but not limited to: cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice (such as rats, mice), pigs, cows, sheep, horses, humans, etc., preferably primates, more preferably humans.

[0061] In the present invention, the "therapeutically effective amount" refers to the amount of a pharmaceutically active ingredient that will cause a biological or medical response in an individual against a disease, disorder and / or symptom, for example, the amount of the composition or product of the present invention that brings a pharmacologically positive effect to the individual. The pharmacologically positive effects include, but are not limited to, reducing or inhibiting enzyme or protein activity or improving symptoms, alleviating disorders, slowing down or delaying the disease process or preventing diseases, etc.

[0062] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as a limitation of the present invention. For those not specified in the embodiments regarding specific technologies or conditions, they shall be carried out according to the technologies or conditions described in the literature in the art or according to the product specifications. For reagents or instruments not specified by the manufacturer, they are all conventional products that can be obtained through commercial purchase.

[0063] The classification and naming of the VB165 strain involved in the embodiments of the present invention is Lactobacillus plantarum ( Lactobacillus plantarum ), the preservation unit is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms. The preservation date is September 28, 2022, and the preservation number is CGMCC No. 25839. The address is: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing.

[0064] The taxonomic name of the VB255 strain involved in the embodiment of the present invention is Lactobacillus rhamnosus ( Lactobacillusrhamnosus ), the preservation unit is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms. The preservation date is March 31, 2023, and the preservation number is CGMCC No. 26968. The address is: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing.

[0065] The taxonomic name of the VB301 strain involved in the embodiment of the present invention is Bifidobacterium animalis subsp. lactis ( Bifidobacterum animalis subsp. lactis ), the preservation unit is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms. The preservation date is July 24, 2023, and the preservation number is CGMCC No. 27998. The address is: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing.

[0066] The BMZ140526 strain (Bifidobacterium animalis) involved in the embodiment of the present invention was purchased from Ningbo Mingzhou Biotechnology Co., Ltd.

[0067] The zebrafish involved in the embodiment of the present invention were all raised in fish culture water at 28 °C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, and the conductivity was 450 - 550 μS / cm; pH was 6.5 - 8.5; hardness was 50 - 100 mg / LCaCO3). They were provided by the breeding center of Huante Biotechnology. The experimental animal use license number is: SYXK (Zhe) 2022 - 0004. The feeding management meets the requirements of international AAALAC certification (certification number: 001458), and the IACUC ethical review number is: IACUC - 2025 - 11001 - 01.

[0068] Example 1: Efficacy evaluation of improving sarcopenia (behavioral science) Randomly select 3 Dpf (3 days post-fertilization) wild-type AB strain zebrafish into 6-well plates, with 30 zebrafish in each well. Randomly divide the zebrafish in different wells into a normal control group, a positive control group, a model control group, and 5 experimental groups. Among them, the experimental groups are divided into the probiotic VB165+VB255 group (the ratio of the viable cell numbers of the two bacteria is 1:1), the probiotic VB165+VB301 group (the ratio of the viable cell numbers of the two bacteria is 1:1), the probiotic VB255+VB301 group (the ratio of the viable cell numbers of the two bacteria is 1:1), the probiotic VB165+VB255+VB301 group (the ratio of the viable cell numbers of the three bacteria is 1:1:1), and the probiotic VB165+VB301+BMZ140526 group (the ratio of the viable cell numbers of the three bacteria is 1:1:1).

[0069] The normal control group was given 3 mL of fish-raising water. In each experimental group, the probiotic combined bacterial powder was dissolved in fish-raising water at a concentration of 1×10 7 CFU / mL. The positive control group was given whey protein powder at a concentration of 62.5 μg / mL dissolved in fish-raising water, and the volume of each well was 3 mL. In addition, except for the normal control group, dexamethasone at a concentration of 2 μmol / L was added to the fish-raising water in the other groups to establish a zebrafish sarcopenia model. That is, in the experimental groups, the fish-raising water dissolved the probiotic combined bacterial powder and dexamethasone at the same time, in the positive control group, the fish-raising water dissolved whey protein powder and dexamethasone at the same time, and in the model control group, the fish-raising water only dissolved dexamethasone. The liquid was changed every day. After treatment at 28°C for 4 days, 10 zebrafish were randomly selected from each experimental group and transferred to 96-well plates, 1 fish per well, and 200 μL / well of fish-raising water was given. The total movement distance of the zebrafish within 1 h was measured using a zebrafish behavior analysis system, and the statistical analysis results of this index were used to evaluate the efficacy of the sample in improving sarcopenia. The statistical treatment results were expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software. p<0.05 indicated that the difference was statistically significant. The results are as 图1 shown. It can be seen from the figure that compared with the model control group, the probiotic composition has the efficacy of improving sarcopenia, specifically manifested as an increase in the total movement distance, and the VB165+VB255+VB301 group has a better effect. Example 2: Evaluation of the efficacy in improving sarcopenia (ATP content) Randomly select 3 Dpf (3 days post-fertilization) wild-type AB strain zebrafish into 6-well plates, with 30 zebrafish in each well. The zebrafish in different wells were randomly divided into a normal control group, a positive control group, a model control group, and 5 experimental groups. The experimental groups were the probiotic VB165 + VB255 group (the ratio of the viable cell numbers of the two bacteria was 1:1), the probiotic VB165 + VB301 group (the ratio of the viable cell numbers of the two bacteria was 1:1), the probiotic VB255 + VB301 group (the ratio of the viable cell numbers of the two bacteria was 1:1), the probiotic VB165 + VB255 + VB301 group (the ratio of the viable cell numbers of the three bacteria was 1:1:1), and the probiotic VB165 + VB301 + BMZ140526 group (the ratio of the viable cell numbers of the three bacteria was 1:1:1).

[0070] The normal control group was given 3 mL of fish-raising water. In each experimental group, the probiotic combined bacterial powder was dissolved in fish-raising water at a concentration of 1×10 7 CFU / mL. The positive control group was given whey protein powder at a concentration of 62.5 μg / mL dissolved in fish-raising water, and the volume of each well was 3 mL. In addition, except for the normal control group, dexamethasone at a concentration of 2 μmol / L was added to the fish-raising water in the other groups to establish a zebrafish sarcopenia model. That is, in the experimental groups, the probiotic combined bacterial powder and dexamethasone were dissolved in the fish-raising water at the same time, in the positive control group, whey protein powder and dexamethasone were dissolved in the fish-raising water at the same time, and in the model control group, only dexamethasone was dissolved in the fish-raising water. The liquid was changed every day. After treatment at 28°C for 4 days, according to the operation method of the ATP (adenosine triphosphate) content assay kit, a multifunctional microplate reader was used to collect data and analyze the ATP content in zebrafish to evaluate the efficacy of the samples in improving sarcopenia based on the statistical analysis results of this index. The statistical treatment results were expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software, and p < 0.05 indicated that the difference was statistically significant. The results are as 图2 shown. As can be seen from the figure, compared with the model control group, the probiotic composition can improve sarcopenia, specifically manifested as an increase in ATP content, and the VB165 + VB255 + VB301 group had a better effect.

[0071] Example 3: Evaluation of the efficacy in improving sarcopenia (muscle tissue pathology) Randomly select wild-type AB strain zebrafish at 3 Dpf (3 days post-fertilization) and place 30 zebrafish in each well of a 6-well plate. Randomly divide the zebrafish in different wells into a normal control group, a positive control group, a model control group, and 5 experimental groups. Among them, the experimental groups are the probiotic VB165 + VB255 group (the ratio of the viable cell numbers of the two bacteria is 1:1), the probiotic VB165 + VB301 group (the ratio of the viable cell numbers of the two bacteria is 1:1), the probiotic VB255 + VB301 group (the ratio of the viable cell numbers of the two bacteria is 1:1), the probiotic VB165 + VB255 + VB301 group (the ratio of the viable cell numbers of the three bacteria is 1:1:1), and the probiotic VB165 + VB301 + BMZ140526 group (the ratio of the viable cell numbers of the three bacteria is 1:1:1).

[0072] The normal control group was given 3 mL of fish-raising water. In each experimental group, the probiotic combined bacterial powder was dissolved in fish-raising water at a concentration of 1×10 7 CFU / mL. The positive control group was given whey protein powder at a concentration of 62.5 μg / mL dissolved in fish-raising water, and the volume of each well was 3 mL. In addition, except for the normal control group, dexamethasone at 2 μmol / L was added to the fish-raising water in the other groups to establish a zebrafish sarcopenia model. That is, in the experimental groups, the fish-raising water dissolved the probiotic combined bacterial powder and dexamethasone at the same time, the fish-raising water in the positive control group dissolved whey protein powder and dexamethasone at the same time, and the fish-raising water in the model control group only dissolved dexamethasone. The liquid was changed every day. After treatment at 28°C for 4 days, the zebrafish in each group were fixed, dehydrated, embedded, sectioned, stained with H&E, etc., and the muscle tissue pathology was examined to evaluate the efficacy of the samples in improving sarcopenia. The results are as 图3 shown. As can be seen from the figure, the muscle tissue morphology of the zebrafish in the normal control group was normal, the muscle cells were thin and long, and the arrangement was neat and tight. The muscle tissue structure of the model control group was loose and the arrangement was irregular, indicating that the model was successfully established. The muscle tissue of the zebrafish in the positive control whey protein powder 62.5 μg / mL concentration group was similar to that of the normal control group and the arrangement was regular, indicating that whey protein powder has the efficacy of improving sarcopenia. The muscle tissue morphology of the zebrafish in each probiotic composition group was significantly improved compared with the model control group, and the arrangement was regular, indicating that the probiotic composition has the efficacy of improving sarcopenia. Among them, the VB165 + VB255 + VB301 group had a better effect.

[0073] Example 4: Effect of compound probiotics on the weight gain of aged mice 6-month-old healthy male C57BL / 6J mice, temperature 20 - 26°C, humidity 40% - 70%, 12h light-dark cycle, all mice were allowed to eat and drink freely, and were adaptively fed for 7 days.

[0074] Mice with similar body weights were randomly divided into 7 groups, with 10 mice in each group, namely the normal control group, the model group, the probiotic VB165 + VB255 group (the ratio of the viable cell counts of the two bacteria is 1:1), the probiotic VB165 + VB301 group (the ratio of the viable cell counts of the two bacteria is 1:1), the probiotic VB255 + VB301 group (the ratio of the viable cell counts of the two bacteria is 1:1), the probiotic VB165 + VB255 + VB301 group (the ratio of the viable cell counts of the three bacteria is 1:1:1), and the probiotic VB165 + VB301 + BMZ140526 group (the ratio of the viable cell counts of the three bacteria is 1:1:1).

[0075] The normal control group was given normal diet feed and free drinking water. The model group was given high-fat diet feed and free drinking water to induce an obesity model. The probiotic composition group was given high-fat diet feed and free drinking water. The control group and the model group were intragastrically administered 400 μL of deionized water every day; the probiotic combination group was intragastrically administered 400 μL of a probiotic combination powder solution suspended in deionized water per mouse per day, and the total viable cell count of the probiotics reached 1×10 9 CFU. The continuous intervention lasted for 18 weeks. The body weights of the mice were weighed with an electronic balance at fixed times every three weeks, and the body weight change curves were recorded and plotted to observe the body weight increase and decrease trends of the mice in different groups.

[0076] The results of the body weight changes of the mice are as 图4 shown. During the test period, the body weights of the mice in the normal control group remained basically unchanged, maintaining at about 27 g, and the physical signs were good. The mice in the model group and the probiotic experimental groups continued to grow normally, showing obesity, and their body weights were significantly higher than those of the normal control group. Compared with the model group, the body weight increase of the mice in the probiotic experimental groups was less than that of the model group, but this difference was not significant. Among them, in the VB165 + VB255 + VB301 group, starting from 12 weeks after administering the probiotic solution, at the 15th week and the 18th week, the body weight increase of the mice in this group was significantly lower than that of the model group. The results show that feeding the VB165 + VB255 + VB301 compound probiotic powder to mice for more than 12 weeks can significantly inhibit the body weight growth of mice fed a high-fat diet, showing good weight loss potential.

[0077] In the description of this specification, the description with reference to terms such as "one embodiment", "some embodiments", "example", "specific example", or "some examples" means that the specific features, structures, materials, or characteristics described in connection with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic expressions of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials, or characteristics described can be combined in a suitable manner in any one or more embodiments or examples. In addition, without contradiction, those skilled in the art can combine and combine the different embodiments or examples described in this specification and the features of different embodiments or examples.

[0078] Although the embodiments of the present invention have been shown and described above, it can be understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those of ordinary skill in the art can make changes, modifications, substitutions, and variations to the above embodiments within the scope of the present invention.

Claims

1. A composition comprising probiotics, characterized in that Includes Lactobacillus plantarum ( Lactobacillus plantarum )、Lactobacillus rhamnosus( Lactobacillus rhamnosus ) and Bifidobacterium animalis subsp. lactis ( Bifidobacterium animalis subsp. lactis ) at least two of the following; The Lactobacillus plantarum is deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, with a deposit date of September 28, 2022 and a deposit number of CGMCC No. 25839. The Lactobacillus rhamnosus is deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, the deposit date is March 31, 2023, and the deposit number is CGMCC No.26968; The preservation unit of the animal Bifidobacterium lactis subspecies is the General Microbiology Center of the China Microbiological Culture Collection Administration, the preservation time is July 24, 2023, and the preservation number is CGMCC No.27998.

2. The composition according to claim 1, characterized in that The Lactobacillus plantarum, the Lactobacillus rhamnosus and the Bifidobacterium animalis subspecies lactis are independently live bacteria, inactivated bacteria or a combination thereof.

3. The composition according to claim 2, characterized in that The total effective viable count of Lactobacillus plantarum, Lactobacillus rhamnosus and Bifidobacterium animalis subspecies lactis is not less than 1×10 6 CFU / g.

4. The composition according to claim 3, characterized in that The ratio of the viable bacterial counts of the plant lactobacillus, the rhamnosus lactobacillus and the animal bifidobacterium lactis subsp. lactis is (1-5):(1-5):(1-5).

5. A product comprising a probiotic composition, characterized in that The product comprises the composition according to any one of claims 1 to 4.

6. The product according to claim 5, characterized in that The product includes any one of medicine, food and health care product.

7. The product according to claim 6, characterized in that The medicament further includes a pharmaceutically acceptable carrier.

8. The product according to claim 6, characterized in that The food also includes edible raw and auxiliary materials.

9. Use of the composition according to any one of claims 1 to 4 or the product according to any one of claims 5 to 8 in the preparation of a medicament for preventing and treating sarcopenia obesity.

10. Use of the composition according to any one of claims 1 to 4 or the product according to any one of claims 5 to 8, wherein the use is selected from at least one of the following: Application in the preparation of preparations for increasing muscle content; Application in the preparation of preparations for improving athletic performance; Application in the preparation of preparations for increasing ATP content; Application in the preparation of preparations for improving muscle tissue morphology; Application in the preparation of preparations for reducing body weight.

Images